Echo Therapeutics,  Inc. (OTCBB: ECTE) – a stock that I personally thought would be trading above $2 by now, recently had its Symphony™ trans-dermal Glucose monitoring system was featured in a March 31, 2010 online magazine article in Scientific American entitled “This Really Won’t Hurt a Bit: Wireless Sensor Promises Diabetics Noninvasive Blood Sugar Readings,” by Larry Greenemeier. The article is certainly worth a read, and if Echo’s Symphony offering can succeed where past attempts and continuous blood glucose monitoring systems have failed, could be very positive for PPS. Management has recently issued some fairly lofty goals for 2010, if and they are met, $1.55 will likely seem like a dream 6 to 12 months down the road.

ECTE got within ONE PENNY of its 52 week high yesterday.Gaping up 18 cents and tapping on $1.99 before pulling back to close at $1.83. With the path now cleared to $1.99, we are looking for a break of the elusive $2 mark in the coming days with a break out that could reach as high as $3!

2010 is shaping up to be a landmark year for Echo Therapeutics, Inc. (OTCBB: ECTE).  The company’s “Symphony” continuous blood glucose monitoring (CBGM) device for Diabetics is expected to become commercially available this year and extensive testing has revealed that the product holds quite a few significant advantages over current market leaders. This is absolutely huge because the addressable market for this product is more than $10 billion and growing with every new case of Diabete’s (sidenote: more than 8% of Americans are now afflicted). Here’s the “quick are dirty” on the Symphony device and the key areas where it is better than multi-billion dollar competitors:

(more…)

Leading healthcare executives and institutional finance firms will embark upon San Francisco next week in search of “the next best thing” in the medical field. Luckily for them, Echo Therapeutics (OTCBB: ECTE) will be there to give it to them.

(more…)

An audio interview conducted with Echo Therapeutics, Inc. (OTCBB: ECTE) CEO Patrick T. Mooney M.D. is now available at www.stockgoodies.com. The interview covers a wide range of topics including the CEO’s experience as both a Wall St. analyst and a surgeon and ECTE’s plan to have at least one, perhaps two, revolutionary FDA-approved medical devices on the market during 2010. We certainly recommend having a listen.

(more…)

Echo Therapeutics, Inc. (OTCBB: ECTE) moved higher on Wednesday, gaining 1.45% or $.02 on 42,950 shares traded. While the recent trading activity has been intriguing, the future potential of the company is what really has us hooked. As mentioned in yesterday’s analyst report, Echo is positioned to dominate the global diabetic monitoring marketplace with its revolutionary needle-free system. The company also has a multitude of additional opportunities at its fingertips.

(more…)

Echo Therapeutics, Inc. (OTCBB:ECTE),  a medical device and specialty pharmaceutical company, is developing a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system for people with diabetes and for use in hospital critical care units, and for people with diabetes and a wide range of transdermal reformulations of specialty pharmaceutical products previously approved by the United States Food and Drug Administration. It offers Symphonytm tCGM System, a next-generation, non-invasive (needle-free), wireless tCGM system designed to provide on-demand blood glucose data. The company was founded in 1989 and is based in Franklin, Massachusetts.

For more information, visit: http://www.echotx.com/